Informace o publikaci

Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data

Autoři

KUBÁČKOVÁ Kateřina BORTLÍČEK Zbyněk PIKUS Tomáš LINKE Zdeněk POKORNÁ Petra VYZULA Rostislav PRAUSOVÁ Jana

Rok publikování 2015
Druh Článek v odborném periodiku
Časopis / Zdroj Future Oncology
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
Doi http://dx.doi.org/10.2217/FON.14.240
Obor Onkologie a hematologie
Klíčová slova bevacizumab; chemotherapy; colorectal cancer; KRAS
Popis Aim: This retrospective analysis investigated the effectiveness of combination therapy with bevacizumab and chemotherapy in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer. Patients & methods: Patients with KRAS wildtype metastatic colorectal cancer in the CORECT registry who initiated treatment with bevacizumab between 2008 and 2012 were enrolled. Overall survival and progression-free survival were the main effectiveness end points. Results: A total of 981 patients were enrolled. Median progression-free survival was 11.3 months (95% CI: 10.7-11.8) and median overall survival was 28.4 months (95% CI: 26.2-30.6). The most common adverse events were thromboembolic disease (4%) and hypertension (3.5%). Conclusion: This retrospective analysis shows the effectiveness of bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info